Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III Study
Top Cited Papers
- 1 October 2011
- journal article
- research article
- Published by Elsevier in Ophthalmology
- Vol. 118 (10) , 2041-2049
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Antagonism of Vascular Endothelial Growth Factor for Macular Edema Caused by Retinal Vein Occlusions: Two-Year OutcomesOphthalmology, 2010
- Ranibizumab for Macular Edema following Branch Retinal Vein OcclusionOphthalmology, 2010
- Ranibizumab for Macular Edema following Central Retinal Vein OcclusionOphthalmology, 2010
- Prospective Study of Intravitreal Ranibizumab as a Treatment for Decreased Visual Acuity Secondary to Central Retinal Vein OcclusionAmerican Journal of Ophthalmology, 2009
- Ranibizumab for the Treatment of Macular Edema Associated with Perfused Central Retinal Vein OcclusionsOphthalmology, 2008
- The 15-Year Cumulative Incidence of Retinal Vein OcclusionArchives of Ophthalmology (1950), 2008
- Ranibizumab for Macular Edema Due to Retinal Vein Occlusions: Implication of VEGF as a Critical StimulatorMolecular Therapy, 2008
- Prevalence and Associations of Retinal Vein Occlusion in AustraliaArchives of Ophthalmology (1950), 1996
- Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ, 1994